Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Relationship Between Cytogenetic Complexity and Peritumoral Edema in High-Grade Astrocytoma

  • Jeong, Kyung-Ho (Department of Neurosurgery, Medical Science Research Center, College of Medicine, Dong-A University) ;
  • Song, Young-Jin (Department of Neurosurgery, Medical Science Research Center, College of Medicine, Dong-A University) ;
  • Han, Jin-Yeong (Department of Laboratory Medicine, College of Medicine, Dong-A University) ;
  • Kim, Ki-Uk (Department of Neurosurgery, Medical Science Research Center, College of Medicine, Dong-A University)
  • Received : 2016.03.30
  • Accepted : 2016.07.27
  • Published : 2016.11.01
⟨ Previous Next ⟩

Abstract

Background: The purpose of the study is to reveal the association of cytogenetic complexity and peritumoral edema volume (PTEV) and its prognostic significance in high-grade astrocytoma patients by culturing patient tumor cells. Methods: Twenty-seven high-grade astrocytoma patients were divided into three groups according to karyotype complexity: normal, non-complex karyotype (NCK), and complex karyotype (CK). Endothelial growth factor receptor (EGFR) amplification was detected by FISH, and its association with chromosome 7 abnormalities was analyzed. Mean PTEV of each group was compared by ANOVA to evaluate the relationship between PTEV and cytogenetic complexity. Results: The PTEV of patients in normal (n=6), NCK (n=8), and CK (n=13) groups were $24.52{\pm}17.73$, $34.26{\pm}35.04$, and $86.31{\pm}48.7cm^3$, respectively (P=0.005). Ten out of 11 patients with EGFR amplification showed abnormalities in chromosome 7. The mean PTEV of EGFR-amplified and non-amplified groups were $80.4{\pm}53.7$ and $41.3{\pm}37.9cm^3$, respectively (P=0.035). The average survival of patients with PTEV less than $90cm^3$ was $30.52{\pm}26.11$ months, while in patients with PTEVs over or equal to $90cm^3$, it was $10.83{\pm}5.53$ months (P=0.007). Conclusions: The results show an association of complex karyotype with the PTEV of highgrade astrocytoma. EGFR amplification plays a significant role in the formation of peritumoral edema, causing PTEV to increase, which is related with survival. This implies that cytogenetic karyotype can be applied as a prognostic factor.

Keywords

Acknowledgement

Supported by : Dong-A University

References

  1. Ohgaki H and Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-89. https://doi.org/10.1093/jnen/64.6.479
  2. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005;11:1462-6. https://doi.org/10.1158/1078-0432.CCR-04-1737
  3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. https://doi.org/10.1056/NEJMoa043330
  4. Walid MS. Prognostic factors for long-term survival after glioblastoma. Perm J 2008;12:45-8.
  5. Barker FG 2nd, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001;51:410-8.
  6. Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, et al. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol 2015;33:1197-213. https://doi.org/10.1200/JCO.2014.55.9575
  7. Das P, Puri T, Jha P, Pathak P, Joshi N, Suri V, et al. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. J Clin Neurosci 2011;18:66-70. https://doi.org/10.1016/j.jocn.2010.04.050
  8. Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 2009;16:748-54. https://doi.org/10.1016/j.jocn.2008.12.005
  9. Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, et al; German Glioma Network. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 2013;19:5146-57. https://doi.org/10.1158/1078-0432.CCR-13-0017
  10. Hur H, Jung S, Jung TY, Kim IY. Cerebellar glioblastoma multiforme in an adult. J Korean Neurosurg Soc 2008;43:194-7. https://doi.org/10.3340/jkns.2008.43.4.194
  11. Jain R, Poisson L, Narang J, Gutman D, Scarpace L, Hwang SN, et al. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology 2013;267:212-20. https://doi.org/10.1148/radiol.12120846
  12. Montgomery RM, Queiroz Lde S, Rogerio F. EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation. Arq Neuropsiquiatr 2015;73:561-8. https://doi.org/10.1590/0004-282X20150059
  13. Shiraishi S, Tada K, Nakamura H, Makino K, Kochi M, Saya H, et al. Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 2002;95:249-57. https://doi.org/10.1002/cncr.10677
  14. Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, Pellin A, Lopez-Guerrero JA, Callaghan R, et al. Association of chromosome 7, chromosome 10 and EGFR gene amplification in glioblastoma multiforme. Clin Neuropathol 2005;24:209-18.
  15. Reardon D, Wen P, Mellinghoff IK. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol 2014;16 (S8):viii7-13. https://doi.org/10.1093/neuonc/nou232
  16. Lal A, Glazer CA, Martinson HM, Friedman HS, Archer GE, Sampson JH, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 2002;62:3335-9.
  17. Schoenegger K, Oberndorfer S, Wuschitz B, Struhal W, Hainfellner J, Prayer D, et al. Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma? Eur J Neurol 2009;16:874-8. https://doi.org/10.1111/j.1468-1331.2009.02613.x
  18. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001;93:1246-56. https://doi.org/10.1093/jnci/93.16.1246
  19. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al; German Glioma Network. Long-term survival with glioblastoma multiforme. Brain 2007;130:2596-606. https://doi.org/10.1093/brain/awm204
  20. Lawrence YR, Mishra MV, Werner‐Wasik M, Andrews DW, Showalter TN, Glass J, et al. Improving prognosis of glioblastoma in the 21st century: who has benefited most? Cancer 2012;118:4228-34. https://doi.org/10.1002/cncr.26685
  21. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002;61:321-8. https://doi.org/10.1093/jnen/61.4.321
  22. Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker FG 2nd. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 2005;11:8600-5. https://doi.org/10.1158/1078-0432.CCR-05-0713
  23. Maire CL and Ligon KL. Molecular pathologic diagnosis of epidermal growth factor receptor. Neuro Oncol 2014;16(S8):viii1-6. https://doi.org/10.1093/neuonc/nou294
  24. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. Cancer Res 2000;60:5879-86.